ProStrakan receive FDA approval for Sancuso

ProStrakan Group has received FDA approval for Sancuso, it’s transdermal granisetron patch for the prevention of chemotherapy-induced nausea and vomiting (CINV).

FDA Acute Chemotherapy-induced Nausea and Vomiting

Eisai and Helsinn have announced that the US FDA has approved a new oral formulation of ALOXI (palonosetron hydrochloride) for the prevention of chemotherapy-induced nausea and vomiting (CINV).

Irribow (ramosetron) approved in Japan for diarrhea predominant IBS

Astellas have announced the Japanese  approval of 5-HT3 antagonist Irribow for the treatment of diarrhea predominant Irritable Bowel Syndrome in Men

Palonosetron (Aloxi) available in US for postoperative nausea and vomiting

Eisai and Helsinn Healthcare have announced the availability of Aloxi (palonosetron hydrochloride) injection 0.075 mg for the prevention of postoperative nausea and vomiting. The FDA approved the drug on February 29, 2008.

Lillys long acting injection olanzapine shows similar profile to Zyprexa

Data prsented at the Schizophrenia International Research Society meeting show Lilly’s long acting injection (LAI) formulation of olanzapine to demonstrate similar efficacy and safety to Zyprexa.

JapanBridge license Asian rights to ProStrakans Sancuso (granisetron transdermal)

JapanBridge have licensed rights to ProStrakan’s Sancuso (granisetron transdermal delivery system) in Japan, China and several other nations throughout South East Asia.

Dynogen present Phase IIa results for DDP225 for IBS

Dynogen have reported that its 5HT3 antagonist DDP225 is efficacious and well tolerated in phase IIa trials. DDP-225 is under development as a treatment for irritable bowel syndrome with diarrhea (IBS-D)

Dynogen present Phase IIa results for DDP733 (pumosetrag) for IBS

Dynogen have reported that its 5HT3 agonist DDP733 (pumosetrag) is efficacious and well tolerated in phase IIa trials. DDP-733 is under development as a treatment for irritable bowel syndrome with constipation (IBS-C)

BioAlliance license European rights to Ondansetron OS from Novadel

BioAlliance have licensed European rights to NovaDel’s Ondansetron Oral Spray from Novadel for US$3 million

Alizyme discontinue IBS drug renzapride

Alizyme have decided to discontinue developmet of renzapride following disappointing Phase III trials in Constipation predominant Irritable Bowel Syndrome (IBS-C). The drug showed “limited clinical improvement” compared with those in the placebo group and “the efficacy shown is not sufficient to justify further development”.